Needham Reiterates Buy on Definitive Healthcare, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ryan MacDonald has reiterated a 'Buy' rating on Definitive Healthcare (NASDAQ:DH) and maintained a $15 price target.
August 15, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ryan MacDonald has reiterated a 'Buy' rating on Definitive Healthcare and maintained a $15 price target.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $15 price target could potentially boost investor confidence in Definitive Healthcare, leading to a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100